Press Releases

September 25, 2020

Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.

September 16, 2020

Surrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine

August 19, 2020

Surrozen Announces Publication of Second Antibody Platform Technology in Scientific Reports

Novel approach to creating R-spondin-mimetics establishes proof-of-concept for targeted regenerative antibodies

Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials

IND Candidates Nominated for the Treatment of Liver Disease and Inflammatory Bowel Disease

Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies

Surrozen is developing first-in-class bi-specific antibodies that selectively stimulate tissue regeneration

Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing

Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing

Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration

Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online

Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research

Award recognizes Dr. Nusse’s seminal contributions to elucidating the mechanism and role of Wnt signaling

Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology

Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies

Surrozen to Present at Cowen and Company 40th Annual Health Care Conference

Surrozen Appoints Dr. Trudy Vanhove as Chief Medical Officer

Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates

Anna Berkenblit, MD, appointed to Surrozen Board of Directors

Surrozen Strengthens Leadership Team with Addition of New CEO and Scientific Co-founder

February 15, 2017

Surrozen Launches Into Regenerative Medicine With $33 Million in Series A Financing Led by The Column Group

Founded on key discoveries from Stanford University that enable selective Wnt pathway activation, Surrozen advances novel regenerative medicines with broad applications for human health